
1. viruses. 2012 oct 29;4(11):2514-57. doi: 10.3390/v4112514.

advanced vaccine candidates lassa fever.

lukashevich is(1).

author information: 
(1)department pharmacology toxicology, school medicine, center 
predictive medicine biodefense emerging infectious diseases, university
of louisville, kentucky, usa. isluka01@louisville.edu

lassa virus (lasv) prominent human pathogen arenaviridae. 
virus transmitted humans rodent reservoir, mastomys natalensis, is
capable causing lethal lassa fever (lf). lasv highest human impact 
any viral hemorrhagic fevers (with exception dengue fever) 
estimated several hundred thousand infections annually, resulting thousands of
deaths western africa. sizeable disease burden, numerous imported cases of
lf non-endemic countries, possibility lasv used an
agent biological warfare make strong case vaccine development. presently
there licensed vaccine lf approved treatment. recently, several 
promising vaccine candidates developed potentially target
different groups risk. purpose manuscript review lasv
pathogenesis immune mechanisms involved protection. current status 
pre-clinical development advanced vaccine candidates tested
in non-human primates discussed. major scientific, manufacturing, and
regulatory challenges also considered.

doi: 10.3390/v4112514 
pmcid: pmc3509661
pmid: 23202493  [indexed medline]

